SAL0120
/ Shenzhen Salubris
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 28, 2026
A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
(clinicaltrials.gov)
- P3 | N=256 | Completed | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
New P3 trial • Cardiovascular • Hypertension
July 22, 2026
A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)
(clinicaltrials.gov)
- P2 | N=320 | Active, not recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
New P2 trial • Chronic Kidney Disease • Nephrology • Renal Disease
1 to 2
Of
2
Go to page
1